With advances in molecular biologic and genomic technology, detailed molecular mechanisms for development of castration-resistant prostate cancer (CRPC) have surfaced. Metastatic prostate cancer (PCa) no longer represents an end stage, with many emerging therapeutic agents approved as effective in prolonging survival of patients from either pre-or post-docetaxel stage. Given tumor heterogeneity in patients, a one-size-fits-all theory for curative therapy remains questionable. With the support of evidence from continuing clinical trials, each treatment modality has gradually been found suitable for selective best-fit patients: e.g., new androgen synthesis inhibitor arbiraterone, androgen receptor signaling inhibitor enzalutamide, sipuleucel-T immunotherapy, new taxane carbazitaxel, calcium-mimetic radium-223 radiopharmaceutical agent. Moreover, several emerging immunomodulating agents and circulating tumor cell enumeration and analysis showed promise in animal or early phase clinical trials. While the era of personalized therapy for CRPC patients is still in infancy, optimal therapeutic agents and their sequencing loom not far in the future.
Current therapeutic regimen in prostate cancer
Prostate cancer (PCa) is the lead malignancy among males in Western countries, accounting for 28% (238,590) of newly diagnosed cancers in United States in 2013 [1] . It has been the second common cause of cancer deaths in men (behind lung cancer) for two decades [1, 2] .
Treatment for clinically localized PCa aims at cure, typically by surgery or radiation. Emerging technologies have also been used for selected patients in low-risk PCa: e.g., high-intensity focused ultrasound (HIFU), cryotherapy, radiofrequency ablation and photodynamic therapy. identification of new pathway-targeted therapeutics. Incidence and mortality rates vary widely across geographic regions and ethnic groups [5] . Of note, Asians have substantially lower prevalence than African Americans and Caucasians, indicating linkage between genetic background and susceptibility [6] . Exact molecular mechanisms of prostate carcinogenesis are not fully elucidated, but it is evident that genetic factors at both germline and somatic levels play key roles in carcinogenesis. It has been increasingly recognized that cancer cells are heterogeneous within the same lesion at both genetic and epigenetic levels, which could translate into functional heterogeneity: e.g., self-renewal properties, tumor-initiating ability [7] . Significant tumor heterogeneity appears within primary and metastatic tumor lesions as well as individual cases, challenging standard approach to cancer management and highlighting the need for personalized cancer therapy.
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer 2 New strategies in CRPC therapy
In the case of advanced PCa, ADT is standard treatment, which initially reduced tumor burden and prostate-specific antigen (PSA) level to low or undetectable level. Most PCa ultimately recurs despite of ADT, presenting with progressively rising of PSA level, termed CRPC.
Docetaxel was regarded as the only reasonable option before 2010.
Additionally, there is no therapeutic agent for patients who experience progression after first-line docetaxel. Recent years have seen a number of novel anticancer drugs for CRPC clinics. The past three years can be considered exceptional due to positive outcomes in Phase III trials. Key antitumor agents showing positive results include taxane cabazitaxel [8, 9] , vaccine sipuleucel-T [10] , cytochrome p450 17 (CYP17) inhibitor abiraterone [11, 12] , androgen-receptor antagonist enzalutamide (formerly known as MDV-3100) [13] [14] [15] , and radioisotope alpharadin (radium 223) [16] . Other promising agents including denosumab [17] , orteronel [18] , ipilimumab [19] and cabozantinib [20, 21] are currently under study. These novel agents are appropriately applied to the CRPC treatment pathway to maximize therapeutic efficacy.
Cabazitaxel, a second-generation taxane, demonstrably improves overall survival when added to prednisone versus mitoxantrone plus prednisone in TROPIC (treatment of hormone-refractory metastatic PCa previously treated with docetaxel-containing regimen) trial: median overall survival is 15.1 months versus 12.7 months in CRPC patients with progression after docetaxel treatment [8] . Progression-free survival also improves in the cabazitaxel-prednisone treatment arm.
Sipuleucel-T, an active cellular immunotherapy, is a type of therapeutic cancer vaccine consisting of autologous peripheral-blood mononuclear cells (PBMCs), including antigen-presenting cells (APCs)
activated ex vivo with a recombinant fusion protein (PA2024) [10] .
PA2024 consists of a prostate-specific acid phosphatase (PAP) fused with granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-cell activator. This regimen can reduce death risk by 22%, representing a 4.1-month improvement in median survival [10] . In conclusion, sipuleucel-T prolonged overall survival among asymptomatic metastatic CRPC (mCRPC) patients. Adverse events are more frequently reported in the sipuleucel-T group, including chills, fever, and headache with mainly Grade 1 or 2 in severity.
Abiraterone acetate blocks androgen biosynthesis by inhibiting 17α-hydroxylase/C17,20-lyase (CYP17). The COU-AA-301 and COU-AA-302 trials established the role of abiraterone in mCRPC patients with or without previous docetaxel chemotherapy. In COU-AA-301 trial, overall survival as primary endpoint was longer with abiraterone acetate-prednisone than with placebo-prednisone (14.8 vs.
10.9 months; P<0.001) [11] . In COU-AA-302 trial, radiographic progression-free survival was also longer with abiraterone-prednisone group than with prednisone alone (16.5 vs. 8.3 months; P<0.001) [12] .
Hence abiraterone acetate significantly prolongs overall survival of mCRPC patients, with or without previous docetaxel chemotherapy.
Enzalutamide, a novel androgen receptor signaling inhibitor, competitively inhibits binding of androgens to the androgen receptor (AR), inhibits AR nuclear translocation, and inhibits association of the AR with DNA [22] . The AFFIRM trail (A multinational phase 3, randomized double-blind, placebo-controlled efficacy and safety study of oral MDV3100 in progressive CRPC previously treated with docetaxel-based chemotherapy) confirms that enzalutamide could benefit men with post-docetaxel CRPC [15] . Enzalutamide is well-tolerated and prolongs overall survival with median survival of 18.4 months, slows disease progression, and improves quality of life in men with post-docetaxel CRPC. It reduces risk of death by 37% relative to placebo [14, 15] . 
Personalized therapy
It is well documented that response to standard therapy differs among patients diagnosed with the same cancer. Obviously, a one-size-fits-all concept is not expected to achieve identical outcome; individualized approach is needed. Progress in understanding intricate molecular TMPRSS2-ERG fusion (around 50%) [27, 28] , 8p loss (30-50%) and 8q gain (20-40%) [29, 30] . Focal amplifications of AR (Xq12) and MYC (8q24), and homozygous focal deletions of PTEN (10q23) and NKX3.1 (8p21) are frequently identified in PCa [31, 32] . Recent CNA study of 218 primary and metastatic tumors added a key role for somatic copy number increases of NCOA2 gene, which encodes an AR coactivator [30] . In detail, besides above descriptions, peaks of deletion targeting
spanning ERG and TMPRSS2 [30] , deletions on 12p13.31-p12.3, which spans ETV6 and DUSP16 as well as CDKN1B [29] were reported. Most common amplified loci include MYC on 8q24.21 and NCOA2 on 8q13.3.
Focal amplification of AR (Xq12) is likewise common but restricted to metastatic tumors. Among mutated genes, the most common is androgen receptor (AR); other oncogenes like IDH1, IDH2, PIK3CA, KRAS, and BRAF do not commonly mutate in PCa [30] . There is no great correlation between histology (Gleason score) and CNAs; the latter could serve as an independent clinical marker from Gleason score [33] .
Integrating CNAs, transcriptome, and mutation data can further conduct core pathway analysis for PCa. Three recognized cancer pathways, PI3K, RAS/RAF, and RB, are ordinarily altered in primary PCa (range:
34-43%) and metastases (74-100%). Of particular interest is PI3K
pathway, altered in nearly half the primaries and all metastases examined [30] . Loss of PTEN function is well documented in PCa: estimated frequency around 40% [34] . PTEN negatively regulates PI3K/Akt pathway; loss of PTEN activity may lead to permanent PI3K/Akt activation. Frequency of PI3K pathway alteration rises substantially when PTEN alteration is considered with INPP4B and PHLPP phosphatase alterations recently implicated in PI3K regulation, the PIK3CA gene itself, and regulatory subunits PIK3R1 and PIK3R3 [26] .
Exploring novel PI3K pathway inhibitors may reap therapeutic benefit [35, 36] .
Genetic alterations highly associated with TMPRSS2-ERG
A recent rearrangement involving the androgen-regulated TMPRSS2 and members of the ETS transcription factor family (ERG, ETV1, ETV4) has been identified in a majority of prostate cancers [27, 37] 
Conventional therapy currently focuses on androgen-dependent activation of AR via its C-terminal ligand-binding domain (LBD).
Mechanisms of therapeutic failure include AR amplification and/or overexpression, gain-of-function AR mutations, intracrine androgen production; overexpression of AR coactivators, expression of constitutively active splice variants of AR, and ligand-independent AR activation through growth factors, cytokines, or aberrant AR phosphorylation [45] . Among AR pathway genes, the most prominent finding is a peak of copy-number gain on 8q13.3 that spans the nuclear receptor coactivator gene NCOA2 [30] . High frequency of NCOA2 gain in primary tumors plus a known role as AR coactivator [46] lends insight into how these two genes collaborate in early PCa progression by enhancing AR transcriptional output. NCOA2 functions as a driver oncogene in primary tumors by increasing AR signaling; in contrast, AR amplification is largely restricted to mCRPC and likely a mechanism of drug resistance rather than a natural step in tumor progression.
Recently developed androgen-ablative and AR antagonist strategies that achieve complete androgen ablation and sufficient suppression of 
Epigenetic alterations
Epigenetics is defined as heritable changes in gene expression caused by mechanisms other than altered DNA sequence. Unlike many other genetic changes, epigenetic processes are reversible and do not change DNA sequence or quantity, though they enhance genomic instability that might lead to oncogenic activation and inactivation of tumor suppressors [52] . Among types of epigenetic change, the most crucial are DNA 
5.

Personalizing treatments with circulating tumor cells (CTCs)
CTCs appear in the bloodstream, having detached from their tumor of origin. A major cause of cancer-associated mortality is tumor metastasis, which depends on successful dissemination to the whole body, mainly through blood. Therefore, CTCs shed into vasculature and possibly on the way to potential metastatic sites arouse obvious interest. Studies in past years have shown CTCs as markers predicting cancer progression and survival in metastatic [54] [55] [56] [57] or even early-stage cancer patients [58] . Assessment CTC using CellSearch has been cleared by the FDA as a prognostic indicator for patients with metastatic breast, prostate, and colorectal cancers [54, 59] . Increasing CTC numbers correlate with aggressive disease, increased metastasis, and decreased time to relapse in CRPC [55, 60, 61] . CTCs could serve as a real-time monitor for progression and marker for survival and thus have potential to guide therapeutic management, indicate therapy effectiveness or necessity, even while metastases are still undetectable, and offer insights into mechanisms of drug resistance. Thus, CTCs not only could be used as a surrogate endpoint marker in clinical trials [62] , but also could become a treatment target [63] . Discrepancy in gene expression between primary tumors and CTCs, as well as heterogeneity within the CTC population, can be observed frequently. To such a degree, it is possible to identify their tissue of origin via expression profiling to detect organ-specific metastatic signatures. This could help to localize small metastatic lesions and afford valuable insight into further diagnostic and therapeutic strategies [64] .
Although 
6.
Personalized immunotherapy for PCa
The concept of immune modulation, which aims at generating a meaningful antitumor immune response, has been extensively evaluated in melanoma and renal cell carcinoma. This principle has been extended to PCa, known as slow-growing and more indolent, which can allow Most treatment regimens for advanced cancer highlight a combination of chemotherapy drugs, or concurrent radio-chemotherapy, raising a possibility that immunotherapy may need combination with conventional therapy to achieve maximal effect. Fortunately, conventional cancer treatments have immunological benefits [72] , making combinatorial trials attractive. In sum, there is strong rationale for combined immunotherapies and/or combining immunotherapy with conventional therapy, but such combination increases complexity for clinical trial design; issues of dosing and sequence become a great challenge.
7.
Conclusions and perspectives
In the past decade, cancer therapy has slowly but steadily transformed from a one-size-fits-all to a more personalized approach, each patient treated according to specific genetic defects of his/her own tumor. Though personalized therapy for CRPC is still in its infancy, ideal therapy tailored for individual CRPC patients continues to advance.
